125 related articles for article (PubMed ID: 28545975)
1. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Ward A; Dong L; Harris JM; Khanna KK; Al-Ejeh F; Fairlie DP; Wiegmans AP; Liu L
Bioorg Med Chem Lett; 2017 Jul; 27(14):3096-3100. PubMed ID: 28545975
[TBL] [Abstract][Full Text] [Related]
2. New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
Shkundina IS; Gall AA; Dick A; Cocklin S; Mazin AV
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34208492
[TBL] [Abstract][Full Text] [Related]
3. RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
Wiegmans AP; Miranda M; Wen SW; Al-Ejeh F; Möller A
Oncotarget; 2016 Sep; 7(37):60087-60100. PubMed ID: 27507046
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.
Huang F; Mazina OM; Zentner IJ; Cocklin S; Mazin AV
J Med Chem; 2012 Apr; 55(7):3011-20. PubMed ID: 22380680
[TBL] [Abstract][Full Text] [Related]
5. Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.
Asan A; Skoko JJ; Woodcock CC; Wingert BM; Woodcock SR; Normolle D; Huang Y; Stark JM; Camacho CJ; Freeman BA; Neumann CA
J Biol Chem; 2019 Jan; 294(2):397-404. PubMed ID: 30478172
[TBL] [Abstract][Full Text] [Related]
6. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.
Huang F; Mazin AV
PLoS One; 2014; 9(6):e100993. PubMed ID: 24971740
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.
Zhu J; Chen H; Guo XE; Qiu XL; Hu CM; Chamberlin AR; Lee WH
Eur J Med Chem; 2015; 96():196-208. PubMed ID: 25874343
[TBL] [Abstract][Full Text] [Related]
8. The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Guney Eskiler G
J Pharm Pharm Sci; 2019; 22(1):599-611. PubMed ID: 31804921
[TBL] [Abstract][Full Text] [Related]
9. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening.
Huang F; Motlekar NA; Burgwin CM; Napper AD; Diamond SL; Mazin AV
ACS Chem Biol; 2011 Jun; 6(6):628-35. PubMed ID: 21428443
[TBL] [Abstract][Full Text] [Related]
10. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
11. The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma.
Chen Q; Cai D; Li M; Wu X
Oncol Rep; 2017 Aug; 38(2):767-774. PubMed ID: 28627709
[TBL] [Abstract][Full Text] [Related]
12. The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Ko JC; Hong JH; Wang LH; Lin YW
Exp Cell Res; 2008 May; 314(8):1881-91. PubMed ID: 18377894
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
14. Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination.
Zhao Q; Guan J; Qin Y; Ren P; Zhang Z; Lv J; Sun S; Zhang C; Mao W
Biomed Pharmacother; 2018 Jan; 97():115-119. PubMed ID: 29080451
[TBL] [Abstract][Full Text] [Related]
15. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.
Lv W; Budke B; Pawlowski M; Connell PP; Kozikowski AP
J Med Chem; 2016 May; 59(10):4511-25. PubMed ID: 27049177
[TBL] [Abstract][Full Text] [Related]
16. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation.
Choi C; Cho WK; Park S; Shin SW; Park W; Kim H; Choi DH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294924
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
20. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.
Budke B; Logan HL; Kalin JH; Zelivianskaia AS; Cameron McGuire W; Miller LL; Stark JM; Kozikowski AP; Bishop DK; Connell PP
Nucleic Acids Res; 2012 Aug; 40(15):7347-57. PubMed ID: 22573178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
